Gene therapies and vaccines rely on viral vectors to deliver genetic material. These vectors are produced in host cell cultures, which also release unwanted host DNA into the solution. This DNA is sticky and can interfere with purification processes.
c-LEcta has developed Denarase, a high-purity endonuclease that removes host cell DNA efficiently. The enzyme works under the same conditions as standard DNA-removal enzymes, ensuring a smooth integration into existing workflows.
Denarase is available as a GMP-grade product, meeting the highest regulatory standards for biopharmaceutical production. After DNA removal, the enzyme itself must also be eliminated. To support this, c-LEcta offers the Denarase ELISA kit, which detects residual enzyme levels with 50 times higher sensitivity than competitor kits—delivering results twice as fast.
Denarase plays a key role in the production of viral vectors used in gene therapy and vaccine development. To learn more, visit denarase.com.
